Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection

US10961299B2 · kind B2 · utility

Assignee

• UNIVERSITY OF MARYLAND, BALTIMORE · US

Inventors

• Hanping Feng · Mountain View, US
• Yongjun Guan · Clarksville, US
• Yongrong Zhang · Columbia, US
• Zhiyong Yang · Beijing, CN
• Lianfa Shi · Baltimore, US

Key dates

• Filing date: Feb 5, 2016
• Grant date: Mar 30, 2021
• Expiry date: Feb 5, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.